THERAPEUTISCHE UMSCHAU最新文献

IF 0.2

THERAPEUTISCHE UMSCHAU Pub Date : 2024-09-01 DOI: 10.23785/TU.2024.05.005

Barbara Ankli

{"title":"[Gout and Nutrition].","authors":"Barbara Ankli","doi":"10.23785/TU.2024.05.005","DOIUrl":"https://doi.org/10.23785/TU.2024.05.005","url":null,"abstract":"Introduction: Gout, the most common arthritis worldwide, is closely linked to cardiovascular disease and metabolic syndrome. The most impor-tant risk factor for developing gout is hyperuricemia. Serum uric acid is the end product of purine metabolism and can be partially influenced by dietary changes. Since a quarter of serum uric acid is excreted via the intestine, there is also a connection with diet here - keyword microbiome. Recently, genetic predispositions and drug therapy for gout have come to the fore. However, since cardiovascular comorbidities exist in high frequency, a dietary adjustment also makes sense to improve the comorbidities. Recently, the focus has shifted away from simply reducing purine intake in favor of introducing a largely plant-based diet. Reducing alcohol consumption makes sense for many reasons but does not lead to a significant reduction in serum uric acid. In addition to drug therapy, however, all possibilities should be exploited to enable a rapid reduction in serum uric acid to the target range; a change in diet can contribute to this. A change in diet can also have a positive effect on the frequency of gout flares. Targeted, structured information for patients promotes their knowledge of the disease and motivation to achieve their serum uric acid (SUA) goal. The right diet may be the personal contribution to quickly reaching the SUA target level and freedom from gout flares.","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"81 5","pages":"164-167"},"PeriodicalIF":0.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142606694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Therapy of gout in 2024]. [2024 年痛风治疗]。

IF 0.2

THERAPEUTISCHE UMSCHAU Pub Date : 2024-09-01 DOI: 10.23785/TU.2024.05.004

Adrian Forster

{"title":"[Therapy of gout in 2024].","authors":"Adrian Forster","doi":"10.23785/TU.2024.05.004","DOIUrl":"https://doi.org/10.23785/TU.2024.05.004","url":null,"abstract":"Introduction: The treatment of gout includes anti-inflammatory therapy and prophylaxis of flare-ups on the one hand and measures for long-term uric acid reduction on the other. Acute arthritis urica is best relieved by intra-articular steroids; systemic steroids, NSAIDs and, in exceptional cases, colchicine are also suitable. For the prophylaxis of relapses, long-term use of colchicine, NSAIDs or low-dose steroids is an option. However, the main pillar of gout therapy is pharmacological reduction of uric acid. The xanthine oxidase inhibitors allopurinol and febuxostat are best suited. The goal is a serum uric acid below 360 µmol/l (\"treat to target\"). The «start low, go slow» strategy reduces the risk of relapses and, in the case of allopurinol, the occurrence of hypersensitivity syndrome. Allopurinol is started at a maximum of 100 mg/d (less in renal insufficiency), followed by a slow upward titration to the required maintenance dose, which may largely exceed 300 mg/d (also in renal insufficiency). Febuxostat is started at a maximum of 40 mg/d and also titrated upwards. The most common cause of insufficient uric acid reduction is unreliable medication intake. In the management of gout, its comorbidities should also be sought and addressed.","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"81 5","pages":"160-163"},"PeriodicalIF":0.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142606696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gicht im Wandel der Zeiten: von der Krankheit der Könige zur Hyperurikämie als Organ-Risikofaktor. 痛风的历史：从国王的疾病到作为器官风险因素的高尿酸血症。

IF 0.2

THERAPEUTISCHE UMSCHAU Pub Date : 2024-09-01 DOI: 10.23785/TU.2024.05.001

Marcel Weber

引用次数: 0

Advances in treatment of hyperuricemia and gout. 高尿酸血症和痛风的治疗进展。

IF 0.2

THERAPEUTISCHE UMSCHAU Pub Date : 2024-09-01 DOI: 10.23785/TU.2024.05.006

Alexandre Dumusc, Alexander So

引用次数: 0

[Imaging in crystal arthropathies]. [晶体关节病的成像技术］

IF 0.2

THERAPEUTISCHE UMSCHAU Pub Date : 2024-09-01 DOI: 10.23785/TU.2024.05.007

Florian Alexander Huber, Roman Guggenberger

引用次数: 0

[Calcium pyrophosphate deposition (CPPD) disease - more than just "pseudogout"]. [焦磷酸钙沉积症（CPPD）--不仅仅是 "假性痛风"]。

IF 0.2

THERAPEUTISCHE UMSCHAU Pub Date : 2024-09-01 DOI: 10.23785/TU.2024.05.003

Tobias Manigold

引用次数: 0

[Gout - clinical presentation]. [痛风--临床表现]。

IF 0.2

THERAPEUTISCHE UMSCHAU Pub Date : 2024-09-01 DOI: 10.23785/TU.2024.05.002

Andreas Krebs

引用次数: 0

[Dyspnea in patients in palliative situations - the invisible symptom]. [姑息治疗患者的呼吸困难--看不见的症状]。

IF 0.2

THERAPEUTISCHE UMSCHAU Pub Date : 2024-08-01 DOI: 10.23785/TU.2024.04.008

Sandra Eckstein

{"title":"[Dyspnea in patients in palliative situations - the invisible symptom].","authors":"Sandra Eckstein","doi":"10.23785/TU.2024.04.008","DOIUrl":"https://doi.org/10.23785/TU.2024.04.008","url":null,"abstract":"Introduction: Dyspnea is a common and distressing symptom in patients with advanced malignant and non-malignant diseases. It is a subjective experience that can only be described by the patients themselves and can be associated with a massive reduction in quality of life, including social isolation and wish to hasten death. Often there is an affective component such as anxiety or panic. Objective parameters do not necessarily correlate with the subjective experience. Health professionals often underestimate and inadequately treat the burden of dyspnea. The introduction of the concept of chronic breathlessness syndrome or acute-on-chronic-breathlessness aims to illustrate the nature of the condition and facilitate the identification and access to appropriate treatment. The management of dyspnea is complex, and for effective treatment, a combination of general, non-pharmacological, and pharmacological measures is usually advisable. Opioids should be offered to patients with incurable cancer and refractory dyspnea for symptom relief. They can be supplemented with benzodiazepines in cases of concomitant anxiety. The administration of oxygen is only indicated in cases of hypoxemia. Key measures include education, self-management skills acquisition and advance care planning for emergency situations.","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"81 4","pages":"145-150"},"PeriodicalIF":0.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142074223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Oral mucosa problems in palliative care]. [姑息治疗中的口腔黏膜问题]。

IF 0.2

THERAPEUTISCHE UMSCHAU Pub Date : 2024-08-01 DOI: 10.23785/TU.2024.04.005

Petra Vayne-Bossert

引用次数: 0

[The challenge of nutrition in palliative care: Eating and drinking - beneficial even at the end of life?] [姑息关怀中的营养挑战：进食和饮水--即使在生命末期也有益？］

IF 0.2

THERAPEUTISCHE UMSCHAU Pub Date : 2024-08-01 DOI: 10.23785/TU.2024.04.007

Silke Walter, Christine Zobrist

{"title":"[The challenge of nutrition in palliative care: Eating and drinking - beneficial even at the end of life?]","authors":"Silke Walter, Christine Zobrist","doi":"10.23785/TU.2024.04.007","DOIUrl":"https://doi.org/10.23785/TU.2024.04.007","url":null,"abstract":"Introduction: Food and nutrition play a major role in our lives. They include physical, psychological as well as cultural and social aspects. Illnesses increase the risk of altered food intake/absorption - of malnutrition. This applies in particular to palliative situations. The causes of malnutrition can be diverse. Malnutrition often leads to reduced performance and can therefore have a major impact on the quality of life and independency of patients. The aim of nutritional therapy interventions is therefore to maintain or improve the quality of life of patients with a life-threatening illness. The initially defined goals can change as the disease progresses. At the beginning of a life-threatening illness, adequate nutritional interventions are usually very effective. However, the benefits of nutritional therapy often change as the disease progresses and they often lose importance. For this reason, decision-making is an important process: Depending on the phase of illness, the prognosis and the patient's preferences, the nutritional therapy interventions needs to be reconsidered in regard of indication, individual benefit and the desired treatment goal on a regular base. As every medical intervention, nutritional therapy must regularly be adapted to the treatment goal if necessary.","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"81 4","pages":"139-144"},"PeriodicalIF":0.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142074227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0